Millennium, J&J and Velcade
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 39 (Table of Contents)
Published: 1 Aug-2003
DOI: 10.3833/pdr.v2003.i39.870 ISSN: 1756-7874
Section: General
Abstract
At the end of June this year, Millennium Pharmaceuticals entered into an agreement with Johnson & Johnson’s subsidiary Ortho Biotech Products for Millennium’s anticancer drug Velcade® (bortezomib) which reduced Millennium’s share down 13% to US$13...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Last Issue PDF
RSS